Literature DB >> 23888323

Antigen-based vaccination and prevention of type 1 diabetes.

Leonard C Harrison1, John M Wentworth, Yuxia Zhang, Esther Bandala-Sanchez, Ralph M Böhmer, Alana M Neale, Natalie L Stone, Gaetano Naselli, Julian J Bosco, Priscilla Auyeung, Maryam Rashidi, Petra Augstein, Grant Morahan.   

Abstract

Insulin-dependent or type 1 diabetes (T1D) is a paradigm for prevention of autoimmune disease: Pancreatic β-cell autoantigens are defined, at-risk individuals can be identified before the onset of symptoms, and autoimmune diabetes is preventable in rodent models. Intervention in asymptomatic individuals before or after the onset of subclinical islet autoimmunity places a premium on safety, a requirement met only by lifestyle-dietary approaches or autoantigen-based vaccination to induce protective immune tolerance. Insulin is the key driver of autoimmune β-cell destruction in the nonobese diabetic (NOD) mouse model of T1D and is an early autoimmune target in children at risk for T1D. In the NOD mouse, mucosal administration of insulin induces regulatory T cells that protect against diabetes. The promise of autoantigen-specific vaccination in humans has yet to be realized, but recent trials of oral and nasal insulin vaccination in at-risk humans provide grounds for cautious optimism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23888323     DOI: 10.1007/s11892-013-0415-7

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  61 in total

Review 1.  Antigen-specific therapy for autoimmune disease.

Authors:  L C Harrison; D A Hafler
Journal:  Curr Opin Immunol       Date:  2000-12       Impact factor: 7.486

2.  GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.

Authors:  Maria Hjorth; Stina Axelsson; Anna Rydén; Maria Faresjö; Johnny Ludvigsson; Rosaura Casas
Journal:  Clin Immunol       Date:  2010-11-01       Impact factor: 3.969

3.  High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM.

Authors:  O Schnell; B Eisfelder; E Standl; A G Ziegler
Journal:  Diabetes       Date:  1997-10       Impact factor: 9.461

4.  Effects of insulin in relatives of patients with type 1 diabetes mellitus.

Authors: 
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

5.  Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.

Authors:  Kirsti Näntö-Salonen; Antti Kupila; Satu Simell; Heli Siljander; Tiina Salonsaari; Anne Hekkala; Sari Korhonen; Risto Erkkola; Jukka I Sipilä; Lotta Haavisto; Marja Siltala; Juhani Tuominen; Jari Hakalax; Heikki Hyöty; Jorma Ilonen; Riitta Veijola; Tuula Simell; Mikael Knip; Olli Simell
Journal:  Lancet       Date:  2008-09-22       Impact factor: 79.321

6.  Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy.

Authors:  Tihamer Orban; Klara Farkas; Heyam Jalahej; Janos Kis; Andras Treszl; Ben Falk; Helena Reijonen; Joseph Wolfsdorf; Alyne Ricker; Jeffrey B Matthews; Nadio Tchao; Peter Sayre; Pete Bianchine
Journal:  J Autoimmun       Date:  2010-06       Impact factor: 7.094

7.  Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes.

Authors:  D L Kaufman; M Clare-Salzler; J Tian; T Forsthuber; G S Ting; P Robinson; M A Atkinson; E E Sercarz; A J Tobin; P V Lehmann
Journal:  Nature       Date:  1993-11-04       Impact factor: 49.962

8.  Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes.

Authors:  I Bergerot; N Fabien; V Maguer; C Thivolet
Journal:  J Autoimmun       Date:  1994-10       Impact factor: 7.094

9.  Effects of oral administration of type II collagen on rheumatoid arthritis.

Authors:  D E Trentham; R A Dynesius-Trentham; E J Orav; D Combitchi; C Lorenzo; K L Sewell; D A Hafler; H L Weiner
Journal:  Science       Date:  1993-09-24       Impact factor: 47.728

10.  Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes.

Authors:  J Tian; M A Atkinson; M Clare-Salzler; A Herschenfeld; T Forsthuber; P V Lehmann; D L Kaufman
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

View more
  17 in total

1.  An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis.

Authors:  Diptendu Chatterjee; Meena Fatah; Deniz Akdis; Danna A Spears; Tamara T Koopmann; Kirti Mittal; Muhammad A Rafiq; Bruce M Cattanach; Qili Zhao; Jeff S Healey; Michael J Ackerman; Johan Martijn Bos; Yu Sun; Jason T Maynes; Corinna Brunckhorst; Argelia Medeiros-Domingo; Firat Duru; Ardan M Saguner; Robert M Hamilton
Journal:  Eur Heart J       Date:  2018-11-21       Impact factor: 29.983

Review 2.  Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.

Authors:  Lucie Barateau; Roland Liblau; Christelle Peyron; Yves Dauvilliers
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

Review 3.  GABAergic system in the endocrine pancreas: a new target for diabetes treatment.

Authors:  Yun Wan; Qinghua Wang; Gerald J Prud'homme
Journal:  Diabetes Metab Syndr Obes       Date:  2015-02-03       Impact factor: 3.168

Review 4.  The mechanisms and applications of T cell vaccination for autoimmune diseases: a comprehensive review.

Authors:  Xin Huang; Haijing Wu; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

Review 5.  Antigen-based immunotherapy for autoimmune disease: current status.

Authors:  Darren Lowell Hirsch; Punita Ponda
Journal:  Immunotargets Ther       Date:  2014-12-16

6.  Occupation with grain crops is associated with lower type 1 diabetes incidence: Registry-based case-control study.

Authors:  Martin Haupt-Jorgensen; Erik Nielsen; Kåre Engkilde; Mia Lerche; Jesper Larsen; Karsten Buschard
Journal:  PLoS One       Date:  2017-07-11       Impact factor: 3.240

Review 7.  Advances in the cellular immunological pathogenesis of type 1 diabetes.

Authors:  Min Li; Lu-Jun Song; Xin-Yu Qin
Journal:  J Cell Mol Med       Date:  2014-03-14       Impact factor: 5.310

8.  An HLA-Transgenic Mouse Model of Type 1 Diabetes That Incorporates the Reduced but Not Abolished Thymic Insulin Expression Seen in Patients.

Authors:  Jeffrey Babad; Riyasat Ali; Jennifer Schloss; Teresa P DiLorenzo
Journal:  J Diabetes Res       Date:  2015-12-28       Impact factor: 4.011

9.  Systemic Administration of Proteoglycan Protects BALB/c Retired Breeder Mice from Experimental Arthritis.

Authors:  Larissa Lumi Watanabe Ishikawa; Priscila Maria Colavite; Thais Fernanda de Campos Fraga-Silva; Luiza Ayumi Nishiyama Mimura; Thais Graziela Donegá França; Sofia Fernanda Gonçalves Zorzella-Pezavento; Fernanda Chiuso-Minicucci; Larissa Doddi Marcolino; Camila Marques; Maura Rosane Valerio Ikoma; Alexandrina Sartori
Journal:  J Immunol Res       Date:  2016-05-18       Impact factor: 4.818

Review 10.  Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes.

Authors:  Minh N Pham; Matthias G von Herrath; Jose Luis Vela
Journal:  Front Immunol       Date:  2016-01-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.